Search Results - "Le Henanff, A"

Fear-avoidance beliefs about back pain in patients with subacute low back pain by Poiraudeau, S., Rannou, F., Baron, G., Henanff, A. Le, Coudeyre, E., Rozenberg, S., Huas, D., Martineau, C., Jolivet-Landreau, I., Garcia-Macé, J., Revel, M., Ravaud, P.

“…The fear-avoidance beliefs of patients with subacute low back pain (LBP) considered at risk for chronic disabling LBP are not well known. The objectives of…”
Get full text

Outcome of subacute low back pain: influence of patients' and rheumatologists' characteristics by Poiraudeau, S., Rannou, F., Le Henanff, A., Coudeyre, E., Rozenberg, S., Huas, D., Martineau, C., Jolivet-Landreau, I., Revel, M., Ravaud, P.

“…Objectives. To assess the outcome of subacute low back pain, to identify the characteristics of patients and physicians which were related to outcome and to…”
Get full text

Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis by Chopin, F, Garnero, P, le Henanff, A, Debiais, F, Daragon, A, Roux, C, Sany, J, Wendling, D, Zarnitsky, C, Ravaud, P, Thomas, T

“…Rheumatoid arthritis (RA) is associated with systemic bone loss, subchondral bone erosion and cartilage degradation under the control of pro-inflammatory…”
Get more information

Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up by Gossec, L., Le Henanff, A., Breban, M., Vignon, E., Claudepierre, P., Devauchelle, V., Wendling, D., Lespessailles, E., Euller-Ziegler, L., Sibilia, J., Perdriger, A., Alexandre, C., Dougados, M.

“…Objective. To evaluate the continuation and safety of treatment with infliximab in ankylosing spondylitis (AS) over a 2-yr period. Methods. This study was an…”
Get full text

Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment by Briot, K, Garnero, P, Le Henanff, A, Dougados, M, Roux, C

“…Objectives: To determine the changes in body weight, body composition, and bone turnover in patients with spondyloarthropathy (SpA) treated with anti-tumour…”
Get full text

Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis by Pham, T, Le Henanff, A, Ravaud, Ph, Dieppe, P, Paolozzi, L, Dougados, M

“…Objective: To evaluate long term efficacy of three iterative courses of three weekly intra-articular (IA) injections of NRD101 in the treatment of symptomatic…”
Get full text

Quality of Reporting of Noninferiority and Equivalence Randomized Trials by Le Henanff, Anne, Giraudeau, Bruno, Baron, Gabriel, Ravaud, Philippe

“…CONTEXT Noninferiority and equivalence trials aim to show that the experimental treatment is not clinically worse than (noninferior) or clinically similar to…”
Get full text

Spinal Tuberculosis: A Longitudinal Study with Clinical, Laboratory, and Imaging Outcomes by Le Page, Laurence, Feydy, Antoine, Rillardon, Ludovic, Dufour, Véronique, Le Hénanff, Anne, Tubach, Florence, Belmatoug, Nadia, Zarrouk, Virginie, Guigui P, Pierre, Fantin, Bruno

“…To study imaging changes associated with spinal tuberculosis (ST) over time and evaluate their association with clinical and laboratory data. Between 1997 and…”
Get full text

Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment by Briot, K, Garnero, P, Le Henanff, A, Dougados, M, Roux, C

“…To determine the changes in body weight, body composition, and bone turnover in patients with spondyloarthropathy (SpA) treated with anti-tumour necrosis…”
Get full text